> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Humacyte Puts Production Ahead Of Pancreas Expansion As Symvess Sales Accelerate
- URL: https://www.bullished.co/humacyte-puts-production-ahead-of-pancreas-expansion-as-symvess-sales-accelerate-16b41741/
- Published: 2026-11-10T15:08:57.000Z
- Updated: 2026-11-10T15:08:57.000Z
- Description: October Symvess revenue reached $0.8 million, while management expects fourth-quarter sales to at least double the third quarter.
- Author: Matteo Parrino
- Tags: Earnings, HUMA, Industry: Healthcare

[Humacyte](https://www.bullished.co/tag/huma/), which develops and manufactures bioengineered human tissues, is prioritizing production and sales over expanding pancreas research, President and Chief Executive Officer Laura E. Niklason said on [Tuesday's earnings call](https://www.benzinga.com/news/26/11/63088086/humacyte-q3-2026-earnings-call-transcript?ref=bullished.co). The company's results release put October Symvess sales at [$0.8 million](https://www.sec.gov/Archives/edgar/data/0001818382/000119312526454402/huma-ex99%5F1.htm?ref=bullished.co), compared with $1.0 million for the entire third quarter.

## More Hospitals, More Symvess Orders

Humacyte Chief Commercial Officer Jim Mercadante expects fourth-quarter Symvess sales to at least double the third quarter's total. Third-quarter [sales rose 151%](https://www.benzinga.com/news/26/11/63088086/humacyte-q3-2026-earnings-call-transcript?ref=bullished.co) from the second quarter's $0.4 million; a year earlier, quarterly sales were $0.7 million.

Hospitals ordering Symvess [increased by 44%](https://www.sec.gov/Archives/edgar/data/0001818382/000119312526454402/huma-ex99%5F1.htm?ref=bullished.co), reaching 49 at September's end versus 34 at the end of the second quarter. Humacyte anticipates adding at least 20 hospitals in the second half of 2026.

Mercadante attributed the improvement to rebuilding the commercial team around vascular-surgery relationships, changing introductory pricing and incentives, and revising education, marketing and training during the second and third quarters.

The turnaround follows a sharp reduction in expectations: analysts' full-year revenue forecasts [fell to $3.50 million](https://finance.yahoo.com/markets/stocks/articles/humacyte-inc-huma-q3-2026-123656370.html?ref=bullished.co) from $6.35 million over the past 90 days. HUMA shares had [lost about 53%](https://finance.yahoo.com/healthcare/articles/humacyte-inc-huma-reports-q3-121501726.html?.tsrc=rss&ref=bullished.co) since the start of 2026\. Shares rose about 22% to $0.55 in Tuesday trading; the company's market value was $126 million.

## Idle Capacity Still Costs Money

Faster sales have yet to eliminate manufacturing overhead. Responding to a Barclays analyst's question about fourth-quarter profitability, Humacyte Chief Financial Officer and Chief Corporate Development Officer Dale Sander said idle-capacity costs would likely continue flowing into product costs during the quarter.

Third-quarter product costs totaled $1.4 million, versus $0.3 million a year earlier. Of the latest total, $0.6 million covered units sold, while $0.8 million primarily covered unused-capacity overhead and royalties.

Sander said successful production near the end of 2025 allowed Humacyte to limit manufacturing runs in 2026\. Management plans a substantial production schedule for 2027 and expects unused-capacity overhead to stop flowing into product costs as manufacturing increases.

Humacyte used $15.0 million of cash in operations during the third quarter, down from $23.9 million a year earlier, which it attributed primarily to lower inventory-production costs. Cash, cash equivalents and restricted cash totaled $64.9 million at September's end. Research spending fell to $14.1 million from $18.1 million in the second quarter and $17.3 million a year earlier.

## Pancreas Work Stays In The Lab

“We don't want to run out, so we're going to [make a lot](https://www.benzinga.com/news/26/11/63088086/humacyte-q3-2026-earnings-call-transcript?ref=bullished.co) more,” Niklason said. The biovascular pancreas project continues at laboratory scale, with a publication on primate research in press. She said additional resources would probably come next year, when cash flow offers more room.

Symvess serves U.S. hospitals treating adults with injured limb arteries who urgently need restored blood flow to avoid limb loss and cannot receive a graft made from their own vein. Humacyte operates an 83,000-square-foot manufacturing facility and is also developing vessels for dialysis access and other conditions.

Humacyte plans to submit its dialysis-access FDA approval application in November, supported by three late-stage studies. Niklason said its target population is all women and men with certain risk factors for failure of standard dialysis-access surgery. That use remains unapproved.

Niklason expects to learn in January whether the dialysis application receives priority review. She said that decision could mean an FDA target decision date in May and a possible June launch, or a September decision date without priority review.

Learn

- [How To Read An Earnings Call Transcript: Start With Guidance, Then Find What's Missing →](https://www.bullished.co/learn/how-to-read-an-earnings-call/)  
How to read an earnings call transcript: check guidance first, look for dropped metrics, compare growth with last quarter, and watch hedged wording.

### Sources

- [Humacyte results release (Form 8-K, EX-99.1)](https://www.sec.gov/Archives/edgar/data/0001818382/000119312526454402/huma-ex99%5F1.htm?ref=bullished.co) — SEC EDGAR
- [Humacyte, Inc. (HUMA) Reports Q3 Loss, Tops Revenue Estimates](https://finance.yahoo.com/healthcare/articles/humacyte-inc-huma-reports-q3-121501726.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance
- [Humacyte GAAP EPS of -$0.06 beats by $0.03, revenue of $1.03M beats by $0.26M (HUMA:NASDAQ) | Seeking Alpha](https://seekingalpha.com/news/4669656-humacyte-gaap-eps-of-0%5F06-beats-by-0%5F03-revenue-of-1%5F03m-beats-by-0%5F26m?ref=bullished.co) — seekingalpha.com
- [Humacyte Q3 2026 Earnings Call Transcript](https://www.benzinga.com/news/26/11/63088086/humacyte-q3-2026-earnings-call-transcript?ref=bullished.co) — benzinga.com
- [Humacyte Inc (HUMA) Q3 2026 Earnings Report Preview: What to Look For](https://finance.yahoo.com/markets/stocks/articles/humacyte-inc-huma-q3-2026-123656370.html?ref=bullished.co) — Yahoo Finance
- [Durham biotech reaches $9M deal to end shareholder lawsuit - Triangle Business Journal](https://www.bizjournals.com/triangle/news/2026/11/08/humacyte-shareholder-lawsuit-symvess-settlement.html?ref=bullished.co) — bizjournals.com

### More on Humacyte

- [Humacyte Opens First Human Heart-Bypass Vessel Study As Its Hospital Customer Base Expands](https://www.bullished.co/humacyte-opens-first-human-heart-bypass-vessel-study-as-its-hospital-customer-base-expands-4d972d81/)

[All Humacyte (HUMA) coverage →](https://www.bullished.co/tag/huma/)